IN8bio, Inc. (INAB) Form 8-K Summary
Business Context and Reporting Period
IN8bio, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 12, 2026. The filing announces the issuance of a press release detailing financial results for the fourth quarter and the full fiscal year ended December 31, 2025. The company is designated as an emerging growth company.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the reported period.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this Form 8-K. The document solely confirms the announcement of results for the period ended December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It explicitly states that the information, including the referenced press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 12, 2026) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate given the lack of specific liquidity data in this summary document.
- Confirm any updates to clinical trial milestones or partnership agreements mentioned in the full press release.
- Check for any forward-looking statements or revised guidance included in the referenced exhibit.